Author Page for Sherene Loi

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study

Number of pages: 170 Posted: 03 Dec 2019

Peter Schmid, Roberto Salgado, Yeon Hee Park, Eva Muñoz-Couselo, Sung-Bae Kim, Joohyuk Sohn, Theodoros Foukakis, Sherko Kuemmel, Rebecca Dent, Lina Yin, Anran Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés and Sherene Loi

Queen Mary University of London - Barts ECMC, Peter MacCallum Cancer Centre - Division of Research, Sungkyunkwan University - Division of Hematology-Oncology, Vall d'Hebron Institute of Oncology, University of Ulsan - Department of Oncology, Yonsei University - Yonsei Cancer Center, Karolinska Institutet, Essen-Mitte Kliniken, National Cancer Centre Singapore, Merck & Co., Inc., Merck & Co., Inc., Merck & Co., Inc., Merck & Co., Inc., Vall d'Hebron Institute of Oncology and Peter MacCallum Cancer Centre

Downloads 68 (891,180)

Citation 6

Sherene Loi

Peter MacCallum Cancer Centre

1

68

6

Scholarly Papers (1)

Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study

Abstract: